MBX Biosciences, Inc. Common Stock (MBX) Stock Score, Valuation & Financial Research

MBX Biosciences, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MBX

MBX Biosciences, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 56.92. These figures are a research snapshot, not a buy or sell recommendation.

What MBX Biosciences, Inc. Common Stock does

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MBX Biosciences is a clinical-stage biopharmaceutical company that does not yet generate revenue from commercial product sales. Its business model focuses on the research, discovery, and development of novel precision peptide therapies for endocrine and metabolic disorders, with the goal of eventually commercializing these candidates upon regulatory approval.

Products and services

  • The company is developing a pipeline of precision peptide therapies using its proprietary PEP platform, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, MBX 4291 for obesity, and imapextide (MBX 1416) for post-bariatric hypoglycemia.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Proprietary PEP platform for peptide drug design Source
  • Strong cash position to fund operations into 2029 Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MBX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 56.92
Market capitalization:
2.71B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -104.29M
Free cash flow:
USD -81.88M
Cash:
USD 54.12M
Total debt:
USD 3.34M
EPS:
USD -2.40

What stands out

  • Free cash flow is USD -81.88M, negative for the stored period.
  • The balance sheet shows USD 54.12M of cash versus USD 3.34M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 50.78M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MBX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MBX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MBX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MBX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MBX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MBX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.